Retina specialists Nancy M. Holekamp, MD, and W. Lloyd Clark, MD, discuss strategies for switching therapies for patients with wet macular degeneration and diabetic macular edema. Drs. Holekamp and Clark share their expertise through two case studies and review the important issues that need to be considered before switching therapies.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
Chesterfield, MO
W. Lloyd Clark, MD
Retina Specialist
Palmetto Retina Center
West Columbia, SC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Nancy M. Holekamp, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint Pharmaceuticals, Gemini Therapeutics, Gyroscope, Katalyst Surgical, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron Pharmaceuticals, Stealth Biosciences, and Thea Laboratoires. Grant/Research Support: Gemini Therapeutics, Genentech, Gyroscope, and Notal Vision. Speaker’s Bureau: Allergan, Apellis, Genentech, Regeneron Pharmaceuticals, and Spark Therapeutics. Stock/Shareholder: Gemini Therapeutics, Katalyst Surgical, and Nacuity.
W. Lloyd Clark, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Genentech/Roche and Regeneron. Grant/Research Support: Genentech/Roche, Kodiak, and Regeneron. Speaker's Bureau: Genentech/Roche and Regeneron.
The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit
Deepak Sambhara, MD
